Triple
T33974898
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | RHINE |
E871107
|
entity |
| Predicate | therapeuticClassStudied |
P177980
|
FINISHED |
| Object | bispecific antibody targeting Ang-2 and VEGF-A |
—
|
LITERAL FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: bispecific antibody targeting Ang-2 and VEGF-A | Statement: [RHINE, therapeuticClassStudied, bispecific antibody targeting Ang-2 and VEGF-A]
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: therapeuticClassStudied Context triple: [RHINE, therapeuticClassStudied, bispecific antibody targeting Ang-2 and VEGF-A]
-
A.
therapeuticSubgroup
Indicates a relationship where one entity is classified as a therapeutic subgroup within the broader therapeutic categorization of another entity.
-
B.
coreTherapeuticArea
Indicates the primary medical or clinical domain in which a therapy, treatment, or product is principally intended to be used.
-
C.
conditionStudied
Indicates that a particular condition (e.g., disease, state, or circumstance) is the focus of study or investigation in a given context.
-
D.
potentialTherapeuticUse
Indicates that something is being considered or investigated as a possible treatment or therapy for a condition or disease.
-
E.
isTherapeuticTargetIn
Indicates that a biological entity (e.g., gene, protein, pathway) is used or proposed as a therapeutic target within a specified disease, condition, or treatment context.
- F. None of above. chosen
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f3499da0188190ab1a4ff06fb06a2a |
completed | April 30, 2026, 12:22 p.m. |
| NER | Named-entity recognition | batch_69f7064e906881909c3186c646145d34 |
completed | May 3, 2026, 8:24 a.m. |
| PD | Predicate disambiguation | batch_69f70100ec1c8190a6b97f50e88891f2 |
completed | May 3, 2026, 8:02 a.m. |
| PDg | Predicate description generation | batch_69f7064d37388190993b2a7305a02b9f |
completed | May 3, 2026, 8:24 a.m. |
Created at: May 1, 2026, 1:50 a.m.